Medicus Pharma Ltd Stock Performance
| MDCX Stock | USD 2.99 0.47 18.65% |
The company secures a Beta (Market Risk) of 3.38, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Medicus Pharma will likely underperform. At this point, Medicus Pharma has a negative expected return of -0.31%. Please make sure to verify Medicus Pharma's treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Medicus Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medicus Pharma Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 267.7 K | |
| End Period Cash Flow | 1.7 M |
Medicus |
Medicus Pharma Relative Risk vs. Return Landscape
If you would invest 456.00 in Medicus Pharma Ltd on October 20, 2024 and sell it today you would lose (157.00) from holding Medicus Pharma Ltd or give up 34.43% of portfolio value over 90 days. Medicus Pharma Ltd is currently does not generate positive expected returns and assumes 10.09% risk (volatility on return distribution) over the 90 days horizon. In different words, 89% of otc bb equitys are less volatile than Medicus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Medicus Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medicus Pharma's investment risk. Standard deviation is the most common way to measure market volatility of otc bb equitys, such as Medicus Pharma Ltd, and traders can use it to determine the average amount a Medicus Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0303
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MDCX |
Estimated Market Risk
| 10.09 actual daily | 89 89% of assets are less volatile |
Expected Return
| -0.31 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medicus Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medicus Pharma by adding Medicus Pharma to a well-diversified portfolio.
Medicus Pharma Fundamentals Growth
Medicus OTC BB Equity prices reflect investors' perceptions of the future prospects and financial health of Medicus Pharma, and Medicus Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medicus OTC BB Equity performance.
| Current Valuation | 28.03 M | ||||
| Price To Earning | (0.21) X | ||||
| Price To Book | 8.53 X | ||||
| EBITDA | (323.24 K) | ||||
| Cash And Equivalents | 1.22 K | ||||
| Total Debt | 1.09 M | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (4.16 M) | ||||
| Total Asset | 1.89 M | ||||
| Retained Earnings | (19.18 M) | ||||
About Medicus Pharma Performance
Evaluating Medicus Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Medicus Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medicus Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Medicus Pharma performance evaluation
Checking the ongoing alerts about Medicus Pharma for important developments is a great way to find new opportunities for your next move. OTC BB Equity alerts and notifications screener for Medicus Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medicus Pharma generated a negative expected return over the last 90 days | |
| Medicus Pharma has high historical volatility and very poor performance | |
| Medicus Pharma Ltd currently holds 1.09 M in liabilities. Medicus Pharma has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Medicus Pharma's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (6.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medicus Pharma Ltd currently holds about 1.22 K in cash with (4.16 M) of positive cash flow from operations. | |
| Latest headline from zacks.com: Do Options Traders Know Something About RadNet Stock We Dont |
- Analyzing Medicus Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medicus Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Medicus Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medicus Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medicus Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medicus Pharma's otc bb equity. These opinions can provide insight into Medicus Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medicus OTC BB Equity Analysis
When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.